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Background. sequential chemotherapy can maintain dose intensity and preclude cumulative toxicity by increasing drug diversity.
Purpose. to investigate the toxicity and eﬃcacy of the sequential regimen of gemcitabine followed by paclitaxel in ﬁrst line
advancedstagenon-smallcelllungcancer(NSCLC)patientswithgoodperformancestatus(PS).Patientsandmethods.gemcitabine
1250mg/m2 was administered on day 1 and 8 of course 1 and 2; Paclitaxel 150mg/m2 on day 1 and 8 of course 3 and 4. Primary
endpoint was response rate (RR), secondary endpoints toxicity and time to progression (TTP). Results. Of the 21 patients (median
age 56, range 38–80 years; 62% males, 38% females) 10% (2/21) had stage IIIB, 90% (19/21) stage IV, 15% PS 0, 85% PS 1. 20% of
patientshadapartialresponse,30%stabledisease,50%progressivedisease.MedianTTPwas12weeks(range6–52weeks),median
overall survival (OS) 8 months (range 1–27 months), 1-year survival was 33%. One patient had grade 3 hematological toxicity, 2
patients a grade 3 peripheral neuropathy. Conclusions. sequential administration of gemcitabine followed by paclitaxel in ﬁrst line
treatment of advanced NSCLC had a favourable toxicity proﬁle, a median TTP and OS comparable with other sequential trials and
might, therefore, be a treatment option for NSCLC patients with high ERCC1 expression.
Copyright © 2009 V. Surmont et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Even with the use of novel chemotherapeutic agents, the
prognosis of patients with advanced NSCLC remains poor.
Platinum-based chemotherapy combined with either gem-
citabine, vinorelbine, paclitaxel, or docetaxel is currently
the mainstay in the treatment of advanced NSCLC[1–5].
Standard therapy for advanced NSCLC results in response
rates of 20% to 40%, a median survival between 8–10
months, and 1-year survival rates between 30% and 50% [1–
3].
Chemotherapy may lead to the selection of chemo-
resistant tumor clones. Frequent exposure to diﬀerent
cytotoxic agents with brief intervals may inhibit tumor
regrowth and limit the emergence of drug resistant cell
lines [6, 7]. Sequential chemotherapy administration oﬀers
the possibility to increase drug diversity while maintaining
dose intensity, potentially leading to less dose reductions, an
optimal dose intensity, and prolonged treatment duration
and disease control [6, 7].
In order to investigate the validity of this approach,
we decided to conduct a nonrandomized phase II study,
to investigate the toxicity and eﬃcacy in terms of time to
progression and response rate of a sequential single agent
regimen consisting of gemcitabine followed by paclitaxel
in the ﬁrst-line treatment of patients with stage IIIB/IV
NSCLC.2 Journal of Oncology
Paclitaxel Paclitaxel Rest Paclitaxel Paclitaxel Rest
Day 43 Day 50 Day 57 Day 64 Day 72 Day 80
Course 3 Course 4
Gemcitabine Gemcitabine Rest Gemcitabine Gemcitabine Rest
Day 1 Day 8 Day 15 Day 22 Day 29 Day 36
Course 1 Course 2
= 1c y c l e
Figure 1: Treatment schedule.
2. Patientsand Methods
In this multicenter trial patients with stage IIIB (malignant
pleural eﬀusion or N3 due to supraclavicular lymph node
involvement) and stage IV have been enrolled between
2003 and 2006. The study was approved by the ethical
committees of the Erasmus MC and 4 other hospitals.
Patients were included after written informed consent.
Other selection criteria were measurable disease according
to the RECIST criteria [8], age over 18 years, WHO
performance status less than 2, adequate bone marrow
reserve (absolute neutrophil count ≥ 2.0 × 109/L, platelet
count ≥ 100 × 109/L), adequate hepatic function (total
bilirubin ≤ 1.5×upper normal limit, ASAT and ALAT ≤
3.0×upper normal limit, alkaline phosphatase ≤ 2.5×upper
normal limit, total billirubin 1.5–2.5×upper normal limit
a n dA S A To rA L A T3 – 5 ×upper normal limit in case of liver
metastases).
Exclusion criteria were prior treatment with chemother-
apy and the presence of other malignancies (previous or
present), except adequately treated in situ carcinoma of the
cervix or basal cell carcinoma of the skin and a previous
malignancymorethan5yearsagowithoutevidenceofrecur-
rence (except for malignant melanoma, hypernephroma, or
breast cancer).
3. Treatment
Gemcitabine1250mg/m2 wasadministeredintravenouslyon
days 1 and 8 of courses 1 and 2 as a 30-minute infusion.
Paclitaxel 150mg/m2 was administered intravenously on
days 1 and 8 of courses 3 and 4 as a 3-hour infusion. One
course was deﬁned as two weekly doses of chemotherapy
followed by one week of rest and one cycle as 2 courses of
gemcitabine followed by 2 courses of paclitaxel (Figure 1).
At least 1 cycle was administered unless patient refusal or
excessive toxicity precluded further therapy. If there was
no PD after 1 cycle the same treatment schedule could be
repeated up to a maximum of 2 cycles. If PD was observed
at the end of the ﬁrst or second cycle, further treatment was
according to local policy.
4. Efﬁcacy andTolerability Assessments
Study assessments included physical examination, complete
bloodcount,electrocardiogram,tumormeasurements(chest
X-ray, and chest-upper abdomen computed tomography
scan), within 4 weeks before start of the treatment. Routine
blood test for blood chemistry and haematological toxicity
were performed before each chemotherapy administration.
Response evaluation by CT took place after every 2 courses
by RECIST criteria [8]. Toxicity was graded according to the
National Cancer Institute Common Toxicity Criteria version
3 (NCI-CTC) and was assessed every 3 weeks by physical
examination, direct questioning, and haematological and
biochemical parameters.
5.StatisticalConsiderations
It was hypothesized that if the sequential regimen had an
eﬃcacy lower than 25%, it was unlikely to be of interest
and would not result in further investigation. According to
Fleming’s single stage procedure P0 was set at 0.20. The
response percentage that would certainly warrant further
investigation (P1) was set at 0.40. With a power of 0.93
and an α of 0.06 this implies that 35 patients had to be
enrolled. For the power calculation the best response during
the ﬁrst cycle has been used. P-values <. 05 were considered
signiﬁcant.
6. Results
Twenty-one patients have been enrolled in this trial over a
3-year period due to competing trials in the participating
centres. Median age was 56 years (range 38–80 years), 62%
(13/21) was male, 38% (8/21) female, 10% (2/21) had stage
IIIB, 90% (19/21) stage IV, 15% (2/21) ECOG performance
status 0, 85% (18/21) ECOG 1. Ten (47.5%) patients had an
adenocarcinoma, 3 (14.5%) squamous cell carcinoma, and 8
( 3 8 % )h a dl a r g ec e l lc a r c i n o m a .
One non-evaluable patient died one week after the
ﬁrst gemcitabine dose administration due to a cerebral
vascular accident. At that time the platelet count was
normal. Of the 20 evaluable patients 20% (4/20) achieved a
partial response (PR), 30% (6/20) stable disease (SD), andJournal of Oncology 3
Table 1: Overview of the sequential studies reported in the literature.
Study Phase N = Regimen RR
(%) PD(%) MS
(m)
1year
OS
(%)
PFS
(m)
Majorgrade3-4toxicity(%)
Doublet→
Doublet
Gebbia (9) III 400 G + IFO (2) →CDDP + VNR (2)
versus 19 59 NR NR 3.1a Neutropenia 57/67/26/21
Thrombo 32/35/17b/41
Vomiting 13/15/21/23
Asthenia 29/35/35c/50
CDDP + VNR (2) →G+I F O( 2 )
versus 32 33 NR NR 5
C D D P+V N R( u pt o6c y c l e s )
versus 44a 25 9 24 4.1
C D D P+G( u pt o6c y c l e s ) 3 4 3 7 8 . 2 2 0 4
Doublet → SA
Edelman (10) III 204 CBDCA + G (3) →PTX(3)
versus 21 29 9 34 4
Neutropenia 47a/70
Anemia 19/14
CDDP + VNR (3) →DOC(3)
28 22 9 36 4
Thrombocytopenia 37/2a
Fatigue 7a/18
Emesis 5a/24
Toxic deaths 3/3
Clark (11) II 18 CDDP (2) + VNR(2) → DOC (4) 31 44 9.5 44 NR
Leukopenia 45d
Emesis 26d
Toxic deaths 3
Grossi (12) II 51 CDDP + PTX (2) →VNR( 2)→G
(2) 43 25 14 53 6.8
Neutropenia 41
Toxic deaths 1
Kubota (13) III
401 CBDCA + PTX (up to 6)
versus 36a 10 13.8 55.5 6
Neutropenia 54/30a
Neuropathia 21/2a
Toxic deaths 0/2
VNR + G (3) → DOC (3) 23 16 13.1 55.6 5.9
SA→doublet or
triplet
Feliu (14) II
52 PTX (6) → CDDP + GEM + VNR
( u pt o6 ) 5 6 3 1 N R 5 6 9
Neutropenia 20
Neuropathy 12
Emesis 10
Rixe (15) II 32 DOC (4) → CDDP + VDS (4) 17 27 11 47 4.4
N e u t r o p e n i a( g r4 )7 1
Febrile neutropenia 14
Neuropathy 24
SA→SA
Present study II 21 G →PTX 20% 50 83 33
Neutropenia 4
Neuropathy 9
Manegold(16) II-III 338 G +DOC (6)
versus 33a NR 7.3 27 6.3a
Neutropenia 36/27
Infection 17/13
G( 3 )→DOC (3) 22 NR 7.4 25 4.9
Dyspnoe 21/20
Asthenia 12/11
Martoni (17) II 52 G(3) →VNR (until PD) 23 23 10 42 6
Neutropenia 22e
Constipation 3e
Poon (18) II 23 G (3) → CDDP (4) 21 52 14.6 63 3.3 Neutropenia 13
Anemia 134 Journal of Oncology
Table 1: Continued.
Study Phase N = Regimen RR
(%) PD(%) MS
(m)
1year
OS
(%)
PFS
(m)
Majorgrade3-4toxicity(%)
Hirsch (19) II 42 VNR (2) →G 38 36 8 29 3.5
No grade 3-4
tox.
Tibaldi (20) II 56 G( 3 ) → DOC
(3) 16 43 8 34 4.8
Neutropenia 5.4
Thrombopenia 3.6
Mucositis 3.6
Diarrhea 3.6
Asthenia 9
(a) statistically signiﬁcant,
(b) diﬀerence in thrombocytopenia incidence between CT arms was statistically signiﬁcant (P = .0001).
(c) asthenia more frequent in the GC arm than VC arm (50% versus 35%, P = .015).
(d) toxicity evaluated per cycle,
(e) worst toxicity per step,
G: gemcitabine, IFO: ifosfamide; CDDP: cisplatin; VNR: vinorelbine; CBDCA: carboplatin; PTX: paclitaxel; DOC: docetaxel; RR: response rate; MS: median
survival; MPFS: median progression-free survival; NR: not reported; OS: overall survival; PD: progressive disease; SA: single agentNR: not reported.
50% (10/20) progressive disease (PD). Five patients (25%)
progressed after 2 courses of gemcitabine, all of them had an
adenocarcinoma. Median time to progression (TTP) was 12
weeks (range 6–52 weeks), the median overall survival (OS)
8 months (range 1–27 months), and the 1-year survival rate
33%. Toxicity was mild; only one patient developed grade
3 hematological toxicity, in two others there was grade 3
peripheral neuropathy occurring at the second cycle. There
were no treatment-related deaths. No dose reductions were
needed.
7. Discussion
Inthisnon-randomisedphaseIIstudy,thesequentialadmin-
istration of single agent gemcitabine followed by paclitaxel in
the ﬁrst line treatment of advanced NSCLC had a favourable
toxicity proﬁle, a median TTP, and OS comparable with
other sequential trials reported in the literature (Table 1)[ 9–
20].
When we designed our study (2002-2003) Vansteenkiste
et al. reported that treatment of patients with symptomatic
advanced NSCLC with single agent gemcitabine resulted in a
superiorclinical-beneﬁtresponseratecomparedtocisplatin-
based combination chemotherapy. Gemcitabine was equally
eﬀective in controlling “disease-speciﬁc” symptoms, but
superior in controlling “constitutional” symptoms [21].
Therefore, single agent gemcitabine in ﬁrst line treatment
of stage IIIB/IV NSCLC was at that time a valid thera-
peutic choice and we decided to investigate the sequen-
tial administration of two single agent non-cross resistant
chemotherapeutic drugs, gemcitabine, and paclitaxel. In the
present study, paclitaxel was selected as sequential agent
because taxanes do not require the presence of an intact
p53 pathway for apoptosis induction in contrast to DNA-
damagingagentslikegemcitabine[22].Thedoseofpaclitaxel
of 150mg/m2was based on the results of phases I and II
trials [23–25]. Akerley et al. reported on a phase I trial of
weekly paclitaxel administered over 3 hours for 6 consecutive
weeks followed by 2 weeks of rest. From this study the
recommended phase II dose was 175mg/m2/week [23]. In
the subsequent phase II trial this dose-dense regimen led
to a high proportion of grade 3-4 neutropenia and grade
2-3 peripheral neuropathy (32%) [24]. Therefore, in the
CALBG study 9713, weekly paclitaxel at a reduced dose of
150mg/m2/week for 6 consecutive weeks was used followed
by 2 weeks of rest. They demonstrated that this dose-dense
regimen could be administered safely [25].
Because 50% of the participants in our trial had dis-
ease progression and because disease progression occurred
already after 2 courses of single agent gemcitabine, we
decide to close our study prematurely. At that time, it had
also become evident from the literature that single agent
gemcitabine in ﬁrst line treatment of stage IIIB/IV NSCLC
was inferior compared to platinum-based doublets [26, 27].
Even though our study has been closed prematurely, our
data add to our current understanding on the treatment
of NSCLC because they contribute to the concept of
maintenance therapy with non-cross resistant drugs. In a
recentrandomizedphaseIIItrialofmaintenancepemetrexed
plus best supportive care versus placebo plus best supportive
care, PFS was 4 months in the pemetrexed arm versus 2
months in the placebo arm with an hazard ratio (HR) of
0.6 (P<. 00001) and the OS was 13.4 months versus
10.6 months, respectively (HR 0.79, P = .012) [28]. The
phase III trial of immediate versus delayed docetaxel after
ﬁrst line chemotherapy in advanced NSCLC showed also
a superior progression free survival (statistically signiﬁ-
cant) and greater median overall survival (not statistically
signiﬁcant) for the arm with immediate docetaxel [29].
These trials support the rationale of using a non-cross-
resistant third generation agents before disease progression
hasoccurred.Wealsobelievethatasingleagentnonplatinum
approach could be of value in ERCC1 positive patients,
especially in the perspective of individualized treatment.Journal of Oncology 5
Patients with completely resected NSCLC and ERCC1-
negative tumors appeared to beneﬁt from adjuvant cisplatin-
based chemotherapy, whereas patients with ERCC1-positive
tumors did not [30]. A prospective trial of 366 patients,
in which patients with low ERCC1 were selected for
platinum-based therapy (docetaxel, cisplatin), while those
with high ERCC1 expression were directed to alternate non-
platinum therapy (docetaxel, gemcitabine), demonstrated a
signiﬁcantly higher overall response rate in the genotypic
arm compared to the non-selected control arm [31]. The
response rate in the low ERCC1 group receiving platinum
chemotherapy was 53%, but the RR in the high ERCC1
non-platinum arm was 47%, compared to 39% for the non-
selected group receiving platinum therapy. A prospective
phase II feasibility trial in which patient’s therapy was
selected based on ERCC1 expression showed that the low
ERCC1 group treated with gemcitabine/carboplatin and the
high ERCC1 group treated with gemcitabine/docetaxel had a
similar median survival of 13 months and response rates of
44% [32].
Our data also conﬁrm that gemcitabine is less active
in adenoarcinoma’s than that in squamous cell carcinoma’s
[1] because all patients in our trial who progressed after 2
courses of gemcitabine had an adencocarcinoma.
In conclusion, although this non-randomised phase
II study failed to meet the primary eﬃcacy endpoint,
the sequential administration of single agent gemcitabine
followed by paclitaxel in ﬁrst line treatment of advanced
NSCLC had a favourable toxicity proﬁle, a median TTP, and
OS comparable with other sequential trials reported in the
literature and might, therefore, be a treatment option for
NSCLC patients with high ERCC1 expression.
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